RPWA
VRTX icon

Regent Peak Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Regent Peak Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$316K Buy
637
+49
+8% +$21.7K 0.06% 145
2026
Q1 		$263K Buy
588
+21
+4% +$9.79K 0.05% 156
2025
Q4 		$257K Buy
567
+31
+6% +$13.4K 0.05% 154
2025
Q3 		$210K Buy
+536
New +$224K 0.04% 180
2025
Q1 		$278K Buy
573
+17
+3% +$7.92K 0.07% 126
2024
Q4 		$224K Sell
556
-14
-2% -$6.49K 0.05% 150
2024
Q3 		$265K Buy
570
+16
+3% +$7.69K 0.06% 133
2024
Q2 		$260K Buy
554
+13
+2% +$5.64K 0.06% 134
2024
Q1 		$226K Buy
541
+44
+9% +$18.6K 0.06% 147
2023
Q4 		$202K Buy
+497
New +$184K 0.05% 158
2021
Q1 		– Sell
-534
Closed -$126K – 978
2020
Q4 		$126K Buy
+534
New +$123K 0.04% 186

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Regent Peak Wealth Advisors's VRTX Position: Q2 2026 in Review

Regent Peak Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 8.3% in Q2 2026, buying an estimated $21.7K and bringing the position to 637 shares worth $316K. The position accounts for 0.06% of the portfolio, ranked #145.

Regent Peak Wealth Advisors first reported a position in VRTX in Q4 2020 and has held it in 11 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Regent Peak Wealth Advisors held 637 shares of Vertex Pharmaceuticals worth $316K as of Q2 2026.
  • Regent Peak Wealth Advisors bought 49 Vertex Pharmaceuticals shares in Q2 2026, an estimated $21.7K.
  • Vertex Pharmaceuticals made up 0.06% of Regent Peak Wealth Advisors's portfolio in Q2 2026, its #145 holding.
  • Regent Peak Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Regent Peak Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.